DerMap™ Platform
Skin Cancer (e.g., Actinic Keratosis)
Key Facts
About ArrayPatch
ArrayPatch is a clinical-stage, privately-held biotech company developing a novel, polymer-free dissolvable microneedle patch platform called DerMap™. The company is pursuing a fast-track 505(b)(2) regulatory pathway for its lead program, ITZ-DerMap™, targeting the multi-billion dollar nail fungus market, with an initial focus on high-risk diabetic patients. Backed by prestigious awards and a €3M seed round, ArrayPatch is leveraging its platform technology to build a pipeline in dermatology and beyond, including skin cancer and migraine. The leadership team combines scientific, clinical, and commercial expertise to advance its patient-centric, pain-free drug delivery solutions.
View full company profileAbout ArrayPatch
ArrayPatch is a clinical-stage, privately-held biotech company developing a novel, polymer-free dissolvable microneedle patch platform called DerMap™. The company is pursuing a fast-track 505(b)(2) regulatory pathway for its lead program, ITZ-DerMap™, targeting the multi-billion dollar nail fungus market, with an initial focus on high-risk diabetic patients. Backed by prestigious awards and a €3M seed round, ArrayPatch is leveraging its platform technology to build a pipeline in dermatology and beyond, including skin cancer and migraine. The leadership team combines scientific, clinical, and commercial expertise to advance its patient-centric, pain-free drug delivery solutions.
View full company profileAbout ArrayPatch
ArrayPatch is a clinical-stage, privately-held biotech company developing a novel, polymer-free dissolvable microneedle patch platform called DerMap™. The company is pursuing a fast-track 505(b)(2) regulatory pathway for its lead program, ITZ-DerMap™, targeting the multi-billion dollar nail fungus market, with an initial focus on high-risk diabetic patients. Backed by prestigious awards and a €3M seed round, ArrayPatch is leveraging its platform technology to build a pipeline in dermatology and beyond, including skin cancer and migraine. The leadership team combines scientific, clinical, and commercial expertise to advance its patient-centric, pain-free drug delivery solutions.
View full company profileAbout ArrayPatch
ArrayPatch is a clinical-stage, privately-held biotech company developing a novel, polymer-free dissolvable microneedle patch platform called DerMap™. The company is pursuing a fast-track 505(b)(2) regulatory pathway for its lead program, ITZ-DerMap™, targeting the multi-billion dollar nail fungus market, with an initial focus on high-risk diabetic patients. Backed by prestigious awards and a €3M seed round, ArrayPatch is leveraging its platform technology to build a pipeline in dermatology and beyond, including skin cancer and migraine. The leadership team combines scientific, clinical, and commercial expertise to advance its patient-centric, pain-free drug delivery solutions.
View full company profile